revenue growth

Day One Biopharmaceuticals reports 172% revenue growth to $155.4M, driven by OJEMDA sales strength. Company acquires Mersana Therapeutics to expand pipeline.

American Sports shares dropped 4.42% despite beating Q4 earnings, as weak 2026 guidance disappointed investors seeking stronger growth outlook.

TSM reports record financial performance driven by AI chip demand, with revenue up 350% and gross margins near 60%. AI chips now represent 58% of revenue.

Morgan Stanley cuts IonQ price target from $58 to $35 ahead of Q4 results, citing technical challenges and profitability concerns despite strong revenue growth.

Figma rebounds on strong 41% revenue growth and positive free cash flow, but valuation concerns persist as stock remains 80% below IPO price amid profitability questions.

AI-driven insurer Lemonade stock drops below $60 amid market volatility, but 40% revenue growth and strong customer expansion suggest potential investment opportunity.

Tradewinds expands nightlife portfolio through Peppermint Hippo integration, targeting $40M+ revenue in 2026 across Florida, Louisiana, and Texas with long-term 100-venue goal.

Truist plans 4-5% revenue growth through loan expansion and margin improvement, while returning $4 billion via share buybacks alongside dividends.

Biodesix reports 24% full-year 2025 revenue growth to $88.5M, with Q4 surging 41% YoY. Company expects adjusted EBITDA positivity and plans investor roadshow.

Veeva Systems targets $6B revenue by 2030, doubling current business. Stock down 35% recently, but specialized platform and customer switching costs support long-term growth outlook.

Astec Industries declares $0.13 quarterly dividend while integrating $67.5M CWMF acquisition, expecting revenue growth and synergies within the first year.

SoundHound AI reports 127% revenue growth but faces valuation concerns, operating losses, and intense competition from tech giants, making profitability unclear.

DoorDash gains momentum with analysts targeting 20-40% upside on strong 2026 outlook. Q4 results show 40% revenue growth and 51% net income increase year-over-year.

D-Wave Quantum stock plunged 60% from October peak despite 235% revenue growth, as investors question its 299x sales valuation and integration risks from recent acquisition.

Iovance's newly approved melanoma therapy Amtagvi generated $68M in quarterly revenue with strong 52% response rates, positioning the biotech for pipeline expansion across multiple cancer indications.

CrowdStrike reports strong 22% revenue growth but remains unprofitable. Stock down 17% YTD with elevated 21x price-to-sales valuation, raising execution concerns.

Oppenheimer's channel research shows strong cybersecurity demand. CrowdStrike leads endpoint protection; SentinelOne gains partner momentum with Purple AI solution at lower valuation.

Chewy's 84% Autoship metric inflates recurring revenue perception; includes all purchases by subscription customers, not just automated renewals. Actual subscription revenue is lower.

Maestria Partners increased its Shift4 Payments stake to 9.5% amid a 51% stock decline, betting on strong operational fundamentals and attractive valuations.

Alphabet maintains decade-long growth momentum with revenue reaching $400B and 2025 showing 15% revenue growth, 32% net income acceleration despite market volatility.